Metabolic complications after liver transplantation. @entity6 , @entity1007 , @entity101 , and XXXX .

@entity1 @entity101 @entity1007 @entity6 @entity28 @entity229 @entity134 @entity299 @entity165
We retrospectively studied the incidence of @entity6 , @entity1007 , @entity101 , and @entity28 in 123 consecutive adult liver transplant recipients (61 @entity1 and 62 @entity1 ) who were alive at least 1 year after transplantation. We also studied the change in these metabolic complications in 61 @entity1 who subsequently were able to be tapered to 5 mg @entity229 per day. One year after transplantation--a point at which almost all @entity1 were on maintenance immunosuppression and had stable graft function--the incidence of @entity6 was 13% and @entity101 was 69.1%. The overall incidence of @entity1007 (serum @entity165 > 240 ng/ml) was 31% and was more frequent in @entity1 than in @entity1 (38.7% vs. 23.0%, P < 0.06). The incidence of @entity28 at 1 year was 41.9% in @entity1 and 39.3% in @entity1 . With tapering of @entity229 from 10 mg to 5 mg per day in 61 @entity1 , the mean serum @entity165 decreased from 224.6 +/- 65.2 mg/dl to 203.3 +/- 65.5 mg/dl, P < 0.005. With @entity134 tapering, 8 @entity1 were able to discontinue antihypertensive medications and 4 were able to discontinue insulin treatment for @entity6 . Five @entity1 became @entity28 during the @entity134 -tapering period. No @entity1 developed irreversible rejection with @entity134 tapering and no immunologic graft losses occurred more than a year after transplantation. Nine @entity1 who lived a year subsequently died. Of these, 7 @entity1 were @entity6 and 2 died of @entity299 . We conclude that metabolic complications such as @entity6 , @entity101 , and @entity1007 are common later after liver transplantation and that these may contribute to @entity1 morbidity and mortality. In addition, we conclude @entity134 tapering to 5 mg/day does not lead to graft loss and may decrease the incidence and severity of late metabolic complications.
